Elixia — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$694,927	13
2024	Research	$2,116,068	12
2023	Research	$57,846	2
2022	Research	$45,644	2
2021	Research	$552	1

Breakdown

Who paid Research payments · program years 2021–2025

AstraZeneca UK Limited $1,861,269 5 payments
AstraZeneca Pharmaceuticals LP $878,702 14 payments
Vertex Pharmaceuticals Incorporated $130,057 6 payments
E.R. Squibb & Sons, L.L.C. $36,605 2 payments
AbbVie, Inc. $4,355 2 payments
Alexion Pharmaceuticals, Inc. $4,050 1 payment

Studies the money was for Research payments · program years 2021–2025

A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $1,844,211 3 payments
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria $443,968 8 payments
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure $434,734 6 payments
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease $99,632 3 payments
Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment $35,245 1 payment
A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin $30,425 3 payments
A Phase 2b multicentre randomized double-blind placebo-controlled parallel group dose ranging study to assess the efficacy safety and tolerability of zibotentan and dapagliflozin in patients with chronic kidney disease with estimated glomerular filtration rate eGFR between 20 and 60 mL min 1.73 m2 $17,057 2 payments
a phase 3,randomized,double blind,placebo controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with immunoglobulin a nephropathy IgAN $4,050 1 payment
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects with Generalized Anxiety Disorder who have had an Inadequate Response to Antidepressant Therapies $3,132 1 payment
Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment $1,360 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.